← Evidence map

ArticleAnnals of hematology2026

First-line Polatuzumab vedotin plus R-CHP in primary mediastinal B-cell lymphoma: A real-world study bridging the gap of the POLARIX trial.

Xue Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

First-line Polatuzumab vedotin plus R-CHP in primary mediastinal B-cell lymphoma: A real-world study bridging the gap of the POLARIX trial. | OpenQuestion